Quick Search:

uzh logo
Browse by:

Zurich Open Repository and Archive

Maintenance: Tuesday, 5.7.2016, 07:00-08:00

Maintenance work on ZORA and JDB on Tuesday, 5th July, 07h00-08h00. During this time there will be a brief unavailability for about 1 hour. Please be patient.

Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-13978

Dissanayake, S K; Olkhanud, P B; O'Connell, M P; Carter, A; French, A D; Camilli, T C; Emeche, C D; Hewitt, K J; Rosenthal, D T; Leotlela, P D; Wade, M S; Yang, S W; Brant, L; Nickoloff, B J; Messina, J L; Biragyn, A; Hoek, K S; Taub, D D; Longo, D L; Sondak, V K; Hewitt, S M; Weeraratna, A T (2008). Wnt5A regulates expression of tumor-associated antigens in melanoma via changes in signal transducers and activators of transcription 3 phosphorylation. Cancer Research, 68(24):10205-10214.

[img] PDF - Registered users only
View at publisher


There are currently no effective therapies for metastatic melanoma and targeted immunotherapy results in the remission of only a very small percentage of tumors. In this study, we show that the noncanonical Wnt ligand, Wnt5A, can increase melanoma metastasis in vivo while down-regulating the expression of tumor-associated antigens important in eliciting CTL responses (e.g., MART-1, GP100, and tyrosinase). Melanosomal antigen expression is governed by MITF, PAX3, and SOX10 and is inhibited upon signal transducers and activators of transcription 3 (STAT3) activation, via decreases in PAX3 and subsequently MITF expression. Increasing Wnt5A in Wnt5A-low cells activated STAT3, and STAT3 was decreased upon Wnt5A knockdown. Downstream targets such as PAX3, MITF, and MART-1 were also affected by Wnt5A treatment or knockdown. Staining of a melanoma tissue array also highlighted the inverse relationship between MART-1 and Wnt5A expression. PKC activation by phorbol ester mimicked Wnt5A effects, and Wnt5A treatment in the presence of STAT3 or PKC inhibitors did not lower MART-1 levels. CTL activation studies showed that increases in Wnt5A correspond to decreased CTL activation and vice versa, suggesting that targeting Wnt5A before immunotherapy may lead to the enhancement of current targeted immunotherapy for patients with metastatic melanoma.


51 citations in Web of Science®
53 citations in Scopus®
Google Scholar™



1 download since deposited on 26 Feb 2009
0 downloads since 12 months

Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Dermatology Clinic
Dewey Decimal Classification:610 Medicine & health
Date:December 2008
Deposited On:26 Feb 2009 10:05
Last Modified:05 Apr 2016 13:01
Publisher:American Association for Cancer Research
Free access at:Publisher DOI. An embargo period may apply.
Publisher DOI:10.1158/0008-5472.CAN-08-2149
PubMed ID:19074888

Users (please log in): suggest update or correction for this item

Repository Staff Only: item control page